BioMarin Pharmaceutical | BMRN - 销售和管理费用

金融业

USD

USD 8.59B

现金及等价物

USD 2.22B

USD 199.48M

USD 4.61B

USD 793.15M

USD 1.44B

USD 129.65M

USD 146.05M

3.04K

EPS每股收益

USD 0.76

股本和储备

USD 6.21B

USD 571.21M

债务利息支出

USD 14.96M

USD 22.56M

USD 1.43B

USD 10.97B

USD 105.53M

USD 636.56M

USD 129.65M

普通股股本

USD 193.27M

15.28

USD 141.2M

USD 766M

销售和管理费用

USD 258.28M

USD 1.27B

贸易债权人

USD 793.15M

应收帐款人

USD 903.91M

	销售和管理费用	更改		日
Acadia Pharmaceuticals	USD 160.79M		14.06M	2026-03
Agios Pharmaceuticals	USD 38.46M		4.51M	2026-03
Alnylam Pharmaceuticals	USD 282.51M		2.55M	2026-03
Amgen	USD 1.58B		354M	2026-03
Bayer	EUR 3.7B		356M	2026-03
Biogen	USD 554.3M		128.2M	2026-03
BioMarin Pharmaceutical	USD 258.28M		63.92M	2026-03
Gilead Sciences	USD 1.45B		326M	2026-03
Incyte	USD 328.1M		62.31M	2026-03
Insmed	USD 247.26M		34.78M	2026-03
Ionis Pharmaceuticals	USD 151M		21M	2026-03
Moderna	USD 173M		135M	2026-03
Neurocrine Biosciences	USD 318.5M		16.7M	2026-03
PTC Therapeutics	USD 73.89M		13.31M	2026-03
Puma Biotechnology	USD 16.82M		8.15M	2024-09
Regeneron Pharmaceuticals	USD 647.7M		127.3M	2026-03
Roche Holding	CHF 7.28B		3.99B	2025-12
Sangamo BioSciences	USD 9.64M		1.83M	2024-06
Sanofi	EUR 2.75B		455M	2025-12
Sarepta Therapeutics	USD 54.03M		51.35M	2026-03
Ultragenyx Pharmaceutical	USD 88M		1000K	2026-03
United Therapeutics	USD 156.6M		34M	2026-03
Vertex Pharmaceuticals	USD 493.7M		6.7M	2026-03